Business
NeoGenomics Launches RaDaR ST, Expanding Molecular Residual Disease Testing Across Multiple Solid Tumor Types
FORT MYERS, Fla., February 25, 2026--NeoGenomics announced the launch of RaDaR® ST, its circulating tumor DNA assay for detecting molecular residual disease.
About this update from Neogenomics, Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":2390,"height":984,"url":"https://media.zenfs.com/en/business-wire.com/5aa7ca0d7c63933d39cfeeb4277406f1"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/Gu.wGpoH4gCR2TeGYB9bjA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTM5NTtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/5aa7ca0d7c63933d39cfeeb4277406f1","width":960,"height":395},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/1oEpsONgS5go1sHJWQg.0Q--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD05ODg7Y2Y9d2VicA--/https://media.zenfs.com/en/business-wire.com/5aa7ca0d7c63933d39cfeeb4277406f1","width":1200,"height":494}},"lazy":false},{"type":"text","content":"We estimate that MRD represents a $20+ billion addressable market, growing at 30% annually, which we believe is less than 10% penetrated","length":136,"tagName":"p","attribs":{}},{"type":"text","content":"FORT MYERS, Fla., February 25, 2026--(BUSINESS WIRE)--NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced the launch of RaDaR® ST, its circulating tumor DNA (ctDNA) assay for detecting molecular residual disease (MRD).","length":299,"tagName":"p"},{"type":"text","content":""RaDaR ST represents an important advancement in MRD testing, a rapidly growing market that remains largely untapped," said Tony Zook, CEO of NeoGenomics. "By providing patient-specific molecular insights, the test enables clinicians to detect residual disease and recurrence sooner than conventional imaging, supporting more informed treatment decisions at each stage of care. Our goal with RaDaR ST is to give providers reliable, actionable results that can be incorporated into clinical practice and research programs, helping support informed clinical decisions and enable earlier intervention in patient care."","length":635,"tagName":"p"},{"type":"text","content":"RaDaR ST uses patient-specific, tumor-informed panels to detect trace amounts of tumor DNA in blood, often before recurrence is visible on imaging. The assay combines whole-exome sequencing with advanced bioinformatics to track up to 48 tumor-specific variants with a limit of detection at 95% probability (LOD95) of 11 ppm, offering high sensitivity and specificity.*","leng...